Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer.
CCL2
MCP1
diagnostics
liquid biopsy
monocyte chemoattractant protein 1
Journal
Research and reports in urology
ISSN: 2253-2447
Titre abrégé: Res Rep Urol
Pays: England
ID NLM: 101576971
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
11
2021
accepted:
27
01
2022
entrez:
18
2
2022
pubmed:
19
2
2022
medline:
19
2
2022
Statut:
epublish
Résumé
Serum levels of the polypeptide chemokine C-C motif ligand 2 (CCL2) have previously shown potential as a prostate cancer diagnostic and prognostic biomarker. Plasma CCL2 levels may be superior to serum levels as a biomarker because of their potentially lower signal-to-noise ratio. Before initiating a large comparative study of plasma and serum CCL2 levels, we performed a prospective, diagnostic pilot study Of 133 individuals from a clinically relevant population. CCL2 plasma levels were measured using a validated assay kit. Plasma was obtained independently of digital rectal examination. In this pilot study, we found no relationship between CCL2 plasma values and risk of proven prostate cancer, whereas previous studies found a strong diagnostic relationship between CCL2 serum values and prostate cancer. Our contribution to the existing literature strengthens the idea that early in the pathological process, CCL2 mainly circulates in large, membrane-enclosed compartments, whereas plasma CCL2 levels increase markedly during disease progression. We conclude that whereas plasma CCL2 levels are not useful as a diagnostic measure, a ratio of CCL2 plasma to serum levels may prove useful as a marker of disease progression, which warrants further study.
Identifiants
pubmed: 35178362
doi: 10.2147/RRU.S346978
pii: 346978
pmc: PMC8846609
doi:
Types de publication
Journal Article
Langues
eng
Pagination
33-38Informations de copyright
© 2022 Lund et al.
Déclaration de conflit d'intérêts
The authors declare that they do not have any competing interests.
Références
J Biol Chem. 2008 Sep 5;283(36):25057-73
pubmed: 18611860
Cancer Res Treat. 2015 Apr;47(2):306-12
pubmed: 25483747
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585812
J Immunol. 2010 Jan 15;184(2):1092-101
pubmed: 19995900
J Biol Chem. 2009 Dec 4;284(49):34342-54
pubmed: 19833726
Biochim Biophys Acta. 2013 Oct;1830(10):4917-27
pubmed: 23845726
Cancer Manag Res. 2019 Nov 29;11:10043-10050
pubmed: 31819637
World J Urol. 2015 Jul;33(7):1051-6
pubmed: 25179012
J Cell Biochem. 2007 Jun 1;101(3):676-85
pubmed: 17216598
Cancer Res. 2007 Oct 1;67(19):9417-24
pubmed: 17909051
Vaccines (Basel). 2021 Mar 08;9(3):
pubmed: 33800511
Prostate. 2010 Mar 1;70(4):433-42
pubmed: 19866475
J Cell Biochem. 2007 Aug 1;101(5):1292-300
pubmed: 17492768
Cytokine. 2020 Jan;125:154810
pubmed: 31430659
Int J Urol. 2016 Oct;23(10):825-832
pubmed: 27488133
Immunol Res. 2014 May;58(2-3):224-33
pubmed: 24522699
Oncotarget. 2016 Feb 16;7(7):8389-98
pubmed: 26701731
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1717-1727
pubmed: 29477409
Invest New Drugs. 2013 Jun;31(3):760-8
pubmed: 22907596
Cancer Sci. 2019 Jan;110(1):279-288
pubmed: 30426599
Turk J Urol. 2019 Dec;45(Supp. 1):S22-S25
pubmed: 30817270
Am J Mens Health. 2018 Nov;12(6):1807-1823
pubmed: 30203706
Int J Cancer. 2020 Nov 1;147(9):2469-2478
pubmed: 33460126
Cytokine Growth Factor Rev. 2010 Feb;21(1):41-8
pubmed: 20005149
Diagnostics (Basel). 2021 Mar 08;11(3):
pubmed: 33800141